Market Place
Sourcing Support
Neumora To Present At Leerink Global Healthcare Conference
04 Mar 2025 //
GLOBENEWSWIRE
Neumora Shakes Up Phase III MDD Trials After January Miss
04 Mar 2025 //
BIOSPACE
Neumora Reports Q4 & FY24 Results, Provides Business Update
03 Mar 2025 //
GLOBENEWSWIRE
Neumora Therapeutics Announces Leadership Transition
13 Feb 2025 //
GLOBENEWSWIRE
Neumora depression drug fail to meet main goal of late-stage study
02 Jan 2025 //
REUTERS
Neumora Therapeutics Reports Q3 2024 Financial Results & Update
12 Nov 2024 //
GLOBENEWSWIRE
Neumora Therapeutics to Participate in Upcoming Conferences in Nov
06 Nov 2024 //
GLOBENEWSWIRE
Neumora Therapeutics to Report Q3 2024 Results on Nov 12, 2024
29 Oct 2024 //
GLOBENEWSWIRE
Neumora Hosts Roundtable On Navacaprant`s Potential In Neuropsychiatric Disorder
14 Aug 2024 //
GLOBENEWSWIRE
Neumora Therapeutics Reports Q2 2024 Results And Business Update
06 Aug 2024 //
GLOBENEWSWIRE
Neumora Begins Phase 1b Study Of NMRA-511 For Alzheimer`s Agitation
20 Jun 2024 //
GLOBENEWSWIRE
Neumora Initiates Navacaprant Phase 2 Study In Bipolar Depression
14 May 2024 //
GLOBENEWSWIRE
Neumora Q1 2024 Results And Business Update
07 May 2024 //
GLOBENEWSWIRE
Neumora Therapeutics to Participate in Upcoming Conferences in May
06 May 2024 //
GLOBENEWSWIRE
Neumora’s schizophrenia drug hit with clinical hold
16 Apr 2024 //
BIOPHARMADIVE
Neumora`s NMRA-266 Study On Clinical Hold
15 Apr 2024 //
GLOBENEWSWIRE
Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days
13 Mar 2024 //
GLOBENEWSWIRE
Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
07 Mar 2024 //
GLOBENEWSWIRE
Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer
22 Jan 2024 //
GLOBENEWSWIRE
Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
02 Jan 2024 //
GLOBENEWSWIRE
Neumora Therapeutics Appoints Jason Duncan as Chief Legal Officer
12 Dec 2023 //
GLOBENEWSWIRE
Neumora Announces NMRA-266 IND Clearance & Initiation of Phase 1 Clinical Study
27 Nov 2023 //
GLOBENEWSWIRE
Neumora Reports Third Quarter 2023 Financial Results & Provides Business Update
01 Nov 2023 //
GLOBENEWSWIRE
Neumora Therapeutics to Participate in Upcoming Conferences in November
30 Oct 2023 //
GLOBENEWSWIRE
Poseida promotes cell therapy president to CEO; Neumora appoints R&D chief
13 Oct 2023 //
ENDPTS
Neumora Announces Appointment of Robert Lenz as Executive Vice President
10 Oct 2023 //
GLOBENEWSWIRE
Neumora Therapeutics Announces Pricing of Initial Public Offering
14 Sep 2023 //
GLOBENEWSWIRE
Neumora`s big neuroscience plans head toward the Nasdaq in second PhIII
25 Aug 2023 //
ENDPTS
Neumora Announces Initiation of Phase 3 Clinical Program for Navacaprant
18 Jul 2023 //
BUSINESSWIRE
Bob Nelsen`s Company raises a really not-as-big Series B
11 Oct 2022 //
ENDPTS
After $500M unveiling, Neumora returns with sophomore financing
11 Oct 2022 //
FIERCEBIOTECH
Neumora Expands Precision Neuroscience Pipeline; Partners with Vanderbilt
17 Feb 2022 //
BUSINESSWIRE
